Mutaciones de resistencia de virus de la inmunodeficiencia humana tipo 1 en pacientes no tratados de los centros penitenciarios de la Comunidad Valenciana. Estudio REPRICOVA

García-Guerrero, J; Herrero, Agustín Ceba; Vera, Enrique; Almenara, José M; Araújo, Rosa; Saurí, Vicente V; Castellano, Juan C; Fernández-Clemente, Luis; Bedia, Miguel; Llorente, María I; González-Morán, Francisco

doi:10.1016/s0025-7753(02)72350-6

Medicina Clínica

2002

DOI: 10.1016/s0025-7753(02)72350-6

|View full text |Cite

Mutaciones de resistencia de virus de la inmunodeficiencia humana tipo 1 en pacientes no tratados de los centros penitenciarios de la Comunidad Valenciana. Estudio REPRICOVA

J García-Guerrero¹,

Agustín Ceba Herrero²,

Enrique Vera³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2008

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

García-Guerrero¹,

Hoya

Portilla³

et al. 2006

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The aim of this cross-sectional study was to analyse the prevalence of HIV-1 drug-resistance mutations among HIV-1-infected prison inmates in Spain. Treatment-naive and treatment-experienced patients with an HIV RNA viral load of >/=2,000 copies/ml were included. To ensure that the study population was representative of the entire HIV-infected Spanish inmate population, a two-stage conglomerate for selection of the sample was used. In the first stage, 15 prisons were randomly selected, and in the second stage, 38 patients (30 treatment-experienced and 8 treatment-naive) per centre were randomly selected. Genotyping was performed by automatic sequencing. Resistance testing was performed on viral strains from 184 inmates from 12 prisons. Valid sequences were obtained from 133 inmates (90 treatment-experienced and 43 treatment-naive inmates). Most (92.5%) were men and had acquired HIV infection by intravenous drug use (91%); their mean age was 35 years. One or more key resistance mutations were detected in 5 (11.6%) treatment-naive and in 35 (38.6%) treatment-experienced patients. Among treatment-naive and treatment-experienced patients, resistance to nucleoside reverse transcriptase inhibitors was found in 3 (6.9%) and in 20 (22.2%) patients, respectively, resistance to non-nucleoside reverse transcriptase inhibitors in 3 (6.9%) and in 21 (23.3%) patients, and resistance to protease inhibitors in 3 (6.9%) and in 14 (15.5%) patients. Multidrug resistance was detected in 1 of the 43 (2.3%) treatment-naive patients. These findings support the use of resistance testing in HIV-infected inmates who must begin antiretroviral therapy, given the high rate of primary resistance to drugs frequently included in the initial treatment regimens.

show abstract

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

García-Guerrero¹,

Hoya

Portilla³

et al. 2006

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2

García-Guerrero¹,

Herrero²,

Araújo³

et al. 2004

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Unexpected High Rate of Wild-Type HIV-1 Genotype Among Inmates Failing Antiretroviral Therapy

Pontali

Ventura

Bruzzone

et al. 2008

HIV Clinical Trials

View full text Add to dashboard Cite

The prevalence of mutated strains in treatment-naïve individuals of the studied cohort is comparable to what is reported in nonimprisoned naïve subjects of our region. The high prevalence of WT genotypes in ART-failing patients makes it likely that they were not taking their treatments, probably to gain legal benefits from their worsening health conditions. Thus, resistance testing can also be considered as an additional tool for assessing adherence to ART for forensic/medicolegal evaluation. However, further and larger studies are necessary to validate it.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mutaciones de resistencia de virus de la inmunodeficiencia humana tipo 1 en pacientes no tratados de los centros penitenciarios de la Comunidad Valenciana. Estudio REPRICOVA

Cited by 3 publications

References 21 publications

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2

Unexpected High Rate of Wild-Type HIV-1 Genotype Among Inmates Failing Antiretroviral Therapy

Contact Info

Product

Resources

About